Barely Significant
← all excerpts

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.

Indian J Crit Care Med · 2020 · PMC7584850 · PMID 33132558

Europe PMCDOI
1
hedged sentence
0.0330
closest p · 0.7× alpha
0.0330
boldest claim

The sentences

a significant trendp = 0.033actually significant
Secondary Outcome CRP reduction among the inflammatory markers showed a significant trend in the tocilizumab group by day 3 ( p = 0.033) ( Table 4 and Fig. 2 ).

also in 8,733 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.